Skip to main content

Table 1 Patient demographics by PHBR score (< 0.5 vs. ≥ 0.5) (N = 83)

From: MHC-I genotype and tumor mutational burden predict response to immunotherapy

Variable Group N (82) PHBR < 0.5 (N = 32) PHBR ≥ 0.5 (N = 51) Relative risk (95% CI)1 P value2
Sex Male 46 22 (48%) 24 (52%) 1.77 (0.96–3.26) 0.07
Female 37 10 (27%) 27 (73%)
Ethnicity Caucasian 71 27 (38%) 44 (62%) 0.91 (0.44–1.90) > 0.99
Others3 12 5 (42%) 7 (58%)
Age4 (years) < 60 17 6 (35%) 11 (65%) 0.90 (0.44–1.82) > 0.99
≥ 60 66 26 (39%) 40 (61%)
Tumor type Head and neck SCC 9 4 (44%) 5 (56%) 1.18 (0.54–2.58) 0.73
Others 74 28 (38%) 46 (62%)
NSCLC 26 7 (27%) 19 (73%) 0.61 (0.31–1.23) 0.16
Others 57 25 (44%) 32 (56%)
Cutaneous SCC 10 7 (70%) 3 (30%) 2.04 (1.22–3.42) 0.04
Others 73 26 (34%) 48 (66%)
Others5 38 14 (37%) 24 (63%) 0.92 (0.53–1.60) 0.82
Head and neck SCC, NSCLC, and cutaneous SCC 45 18 (40%) 27 (60%)
TMB6 (mutations/mb) < 50 65 21 (32%) 44 (68%) 0.49 (0.28–0.83) 0.048
≥ 50 12 8 (67%) 4 (33%)
< 20 56 18 (32%) 38 (68%) 0.61 (0.35–1.07) 0.12
≥ 20 21 11 (52%) 10 (48%)
< 10 38 11 (29%) 27 (71%) 0.63 (0.34–1.15) 0.16
≥ 10 39 18 (46%) 21 (54%)
PD-1/L1 Therapy Monotherapy 66 26 (39%) 40 (61%) 1.12 (0.55–2.27) > 0.99
Combination 17 6 (35%) 11 (65%)
Overall benefit rate SD ≥ 6 months/PR/CR7 36 17 (47%) 19 (53%) 1.45 (0.84–2.49) 0.25
Others 46 15 (33%) 31 (67%)
PD 32 7 (22%) 25 (78%) 0.45 (0.22–0.91) 0.02
Others 51 25 (49%) 26 (51%)
  1. 1Relative risk for PHBR < 0.5
  2. 2Calculated using Fisher’s exact test
  3. 3Others: African American (N = 2), Asian (N = 4), Hispanic (N = 5), and unknown (N = 1)
  4. 4At time of initiation of treatment with immunotherapy
  5. 5Others: adrenal (N = 1), appendix (N = 4), basal cell carcinoma (N = 3), breast cancer (N = 6), cervical (N = 1), cholangiocarcinoma (N = 1), colorectal (N = 2), duodenal (N = 1), gastroesophageal (N = 5), glioblastoma (N = 2), thyroid (N = 1), prostate (N = 1), rectal squamous cell carcinoma (N = 1), renal cell carcinoma (N = 1), sarcoma (N = 3), urothelial (N = 4), and urethral squamous cell carcinoma (N = 1)
  6. 6TMB was performed on 77 patients
  7. 7One patient had SD, but had not reached to 6 months. Only 82 patients were evaluable for this comparison
  8. Abbreviations: CR complete response, HR hazard ratio, NR not reached to 50%, NSCLC non-small cell lung cancer, OS overall survival, PFS progression-free survival, PD progressive disease, PHBR Patient Harmonic-mean Best Rank, PR partial response, RR relative risk, SCC squamous cell carcinoma, SD stable disease, TMB tumor mutational burden